Veterinary Oncology Licensing Agreement Signed Between SourcingLink.net and NanoSmart Pharmaceuticals, Inc.
April 03 2019 - 7:26AM
InvestorsHub NewsWire
Veterinary Oncology Licensing Agreement Signed Between
SourcingLink.net and NanoSmart Pharmaceuticals, Inc.
San Francisco, CA -- April 3, 2019 -- InvestorsHub NewsWire --
SourcingLink.net, Inc. (SNET), a San Francisco, CA based company,
announced today that it entered into an exclusive, worldwide
licensing agreement with NanoSmart Pharmaceuticals, Inc (NanoSmart)
for the right to use NanoSmart's Anti-Nuclear Antibody
(ANA)-targeted drug delivery technologies to develop and
commercialize chemotherapy drug formulations for veterinary
oncology.
The National Cancer Institute estimated that as many as 12
million pets are diagnosed with cancer each year. The pet cancer
therapeutics market, according to Global Insights
[source: https://gminsights.wordpress.com/tag/pet-cancer-therapeutics-market-size/]
is projected to exceed a revenue of $300 million by 2024, with a
compound annual growth rate of 10% over 2017-2024. In
addition, the Comparative Oncology Program of the National Cancer
Institute is designed to “gain a better understanding of the
biology of cancer and improve the assessment of novel treatments
for humans by treating pet animals with naturally-occurring
cancers.” [source: NCI Center for Cancer
Research: https://ccr.cancer.gov/research]
SourcingLink.net stated, "We are pleased to have licensed the
application of NanoSmart's tumor-targeting technologies to improve
the safety and quality of treatments for animals suffering from
cancer and other diseases. This is a significant extension of our
oncology product portfolio into animal health care to address the
growing need for improved pet cancer therapies that can improve
outcomes and extend lifespan.”
The license includes broad access to NanoSmart’s proprietary
drug delivery approaches, including ANA-targeted nanoparticles, for
the purpose of developing veterinary oncology drug products. Under
the terms of the agreement, NanoSmart will receive restricted
common shares of SNET stock, an upfront fee, an annual maintenance
fee, and a high single-digit royalty on net sales of formulations
that incorporate NanoSmart's intellectual property. Dr. James
Smith, President of NanoSmart, stated, "This additional license
agreement demonstrates the value and broad-applicability of our
drug delivery platform technologies. The development of products
for this market will also support SNET’s and NanoSmart’s mutual
goal to provide new and affordable therapeutic options to those
suffering from this devastating disease. We look forward to
supporting the SNET team to develop and commercialize these novel
products."
About SourcingLink.net
SourcingLink.net, Inc. ("SNET") is a pioneering oncology company
dedicated to developing, manufacturing and commercialization of
therapeutics. SNET licensed Tulynode's patent pending Autologous
Immuno-therapy for durable therapy response using an extracorporeal
device. SourcingLink.net prides itself for having a
world-class Advisory Board that keeps the Company leadership in the
forefront of developing technologies in cancer research,
biotechnology and healthcare. SourcingLink.net is currently
engaging in research and development of therapeutics for oncology.
SourcingLink.net is committed to its core corporate mission
and values of highest U.S. Pharma Code of Conduct standards of
behavior for being in compliance with the laws, regulations,
company directives and guidance.
About NanoSmart Pharmaceuticals, Inc.
NanoSmart® Pharmaceuticals is a privately-held California
corporation that is developing nanoparticle drug delivery platforms
that utilize anti-nuclear antibody (ANA) to target existing drug
therapies to areas of necrosis present in virtually all solid
cancer tumors.
Forward-looking Statements:
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements, which contain words such as
"expect", "believe" or "plan", by their nature address matters that
are, to different degrees, uncertain. These uncertainties may
cause actual future events to be materially different than those
expressed in our forward-looking statements. We do not
undertake to update our forward-looking statements.
For additional Information, please contact at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
email: info@sourcinglink.net
website: www.sourcinglink.net